ClinicalTrials.gg
WithdrawnNCT03385395Updated Apr 10, 2018

Study Comparing Weekly Intravenous Administration of OctaAlpha1 With a Marketed Preparation Glassia® in Subjects With Alpha-1-antitrypsin Deficiency

A Phase 2 interventional study of OctaAlpha1 and Glassia in Alpha 1-Antitrypsin Deficiency, sponsored by Octapharma. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-04-10.

Sponsored by Octapharma · Phase 2, Interventional, and Treatment

Why this study was withdrawn
IND has been closed.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This randomized trial is being conducted to show non-inferiority of OctaAlpha1 compared to Glassia® in terms of the serum trough levels at steady state. This will be conducted in individuals with alpha-1-antitrypsin deficiency and clinical evidence of emphysema.

02

Conditions studied

  • Alpha 1-Antitrypsin Deficiency
03

In context

alpha 1-Antitrypsin Deficiency

142 studies on the registry are indexed under alpha 1-Antitrypsin Deficiency; 32 are open to participants now.

Browse alpha 1-Antitrypsin Deficiency studies →

Lead sponsor

Octapharma is the lead sponsor of 71 studies on the registry; 8 are open to participants now.

Of its 17 completed or terminated interventional studies of FDA-regulated products, 16 (94%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Any subject who needs chronic IV augmentation and maintenance therapy with A1PI because of congenital alpha-1-proteinase inhibitor (A1PI) deficiency and clinically diagnosed emphysema
  • ≥18 years of age
  • Individuals with A1PI serum concentration \<11 µM at screening
  • Following bronchodilators:

    • Initial (pred) between 25% and 75% or
    • If the initial FEV1 was greater than 75% of predicted, a diffusing capacity of the lung for carbon monoxide (DLC O) less than 70% of predicted
  • Following bronchodilators: Initial forced expiratory volume/forced vital capacity (FEV1/FVC) ratio less than 70%
  • Non-smoking for at least 6 months before study treatment starts
  • Able to understand and provide written
  • Women of reproductive age: negative result of pregnancy test (human chorionic gonadotropin [HCG]-based assay) and agreement to use adequate for the duration of the trial

Exclusion criteria

Exclusion Criteria:

  • Any inflammatory condition or malignant tumor in the 7 days before treatment starts that according to investigator judgment might influence the metabolism of an enzyme inhibitor such as A1PI
  • More than one A1PI-deficiency related exacerbation and/or hospitalization during the 3 months before study treatment starts
  • liver or kidney disease in the preceding 6 months before study treatment starts
  • Severe gas exchange abnormality (i.e., PaCO2 ≥46 mmHg)
  • Known IgA deficiency with documented antibodies against IgA
  • History of to blood or plasma derived products, or any component of the product
  • Known presence of antibodies against A1PI
  • Seropositivity for or , -1/2 IgG antibodies
  • Administration of A1PI products in the 4 weeks before study treatment starts
  • Participating in another clinical study currently or during the 3 months before study treatment starts.
  • Live viral vaccination within the last month before study treatment starts
  • A current life-threatening
  • Emergency operation within 3 months before study treatment starts
  • History of, or suspected, alcohol or drug abuse within 1 year before study treatment starts or currently on drug abuse therapy
  • Pregnant and nursing women
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    OctaAlpha1

    Drug: OctaAlpha1

  • Active comparator
    Glassia®

    Drug: Glassia

Interventions

  • DrugOctaAlpha1

    For OctaAlpha1 the standard weekly dose of 60mg/kg will be given for 24 consecutive infusions

  • For Glassia the standard weekly dose of 60mg/kg will be given for 24 consecutive infusions

06

What researchers measure

Primary outcomes

  1. Non-inferiority of OctaAlpha1 compared to Glassia® in terms of the serum trough levels at steady state

    Non-inferiority of OctaAlpha1 compared to Glassia® in terms of the serum trough levels at steady state

    Time frame: 26 weeks

Secondary outcomes

  1. Compare PK parameters following a single dose between the two treatment groups following principles of bio-equivalence testing (AUC)

    Compare PK parameters following a single dose between the two treatment groups calculating area under the plasma concentration-time curve (AUC)-ratio: 90% confidence interval (CI) should lie within 80%-125%.

    Time frame: Time period including days 1 to 14 after first infusion in study

  2. Compare PK parameters following a single dose between the two treatment groups following principles of bio-equivalence testing (Cmax)

    Compare PK parameters following a single dose between the two treatment groups calculating maximum plasma concentration (Cmax)-ratio: 90% CI should lie within 80%-125%

    Time frame: Time period including days 1 to 14 after first infusion in study

  3. Compare PK parameters following a single dose between the two treatment groups following principles of bio-equivalence testing (tmax)

    Compare PK parameters following a single dose between the two treatment groups calculating tmax (time to reach maximum serum concentration)

    Time frame: Time period including days 1 to 14 after first infusion in study

  4. Compare PK parameters following a single dose between the two treatment groups following principles of bio-equivalence testing (t1/2)

    Compare PK parameters following a single dose between the two treatment groups calculating t1/2 (apparent terminal half-life)

    Time frame: Time period including days 1 to 14 after first infusion in study

  5. Compare PK parameters following a single dose between the two treatment groups following principles of bio-equivalence testing (λZ)

    Compare PK parameters following a single dose between the two treatment groups calculating λZ (apparent terminal elimination rate constant determined by log-linear regression analysis)

    Time frame: Time period including days 1 to 14 after first infusion in study

  6. Evaluate descriptively the safety and tolerability of OctaAlpha1 based on occurrence of adverse events

    Evaluate descriptively the safety and tolerability of OctaAlpha1 based on occurrence of adverse events

    Time frame: 26 weeks

  7. Evaluate descriptively the safety and tolerability of OctaAlpha1 based on blood pressure

    Evaluate descriptively the safety and tolerability of OctaAlpha1 based on blood pressure

    Time frame: 26 weeks

  8. Evaluate descriptively the safety and tolerability of OctaAlpha1 based on pulse

    Evaluate descriptively the safety and tolerability of OctaAlpha1 based on pulse

    Time frame: 26 weeks

  9. Evaluate descriptively the safety and tolerability of OctaAlpha1 based on body temperature

    Evaluate descriptively the safety and tolerability of OctaAlpha1 based on body temperature

    Time frame: 26 weeks

  10. Evaluate descriptively the safety and tolerability of OctaAlpha1 based on respiratory rate

    Evaluate descriptively the safety and tolerability of OctaAlpha1 based on respiratory rate

    Time frame: 26 weeks

  11. Evaluate descriptively the safety and tolerability of OctaAlpha1 based on monitoring hematological parameter hematocrit

    Evaluate descriptively the safety and tolerability of OctaAlpha1 based on monitoring hematological parameter hematocrit via lab test

    Time frame: 26 weeks

  12. Evaluate descriptively the safety and tolerability of OctaAlpha1 based on monitoring hematological parameter hemoglobin

    Evaluate descriptively the safety and tolerability of OctaAlpha1 based on monitoring hematological parameter hemoglobin via lab test

    Time frame: 26 weeks

  13. Evaluate descriptively the safety and tolerability of OctaAlpha1 based on monitoring hematological parameter white blood cells

    Evaluate descriptively the safety and tolerability of OctaAlpha1 based on monitoring hematological parameter white blood cells via lab test

    Time frame: 26 weeks

  14. Evaluate descriptively the safety and tolerability of OctaAlpha1 based on monitoring hematological parameter platelet count

    Evaluate descriptively the safety and tolerability of OctaAlpha1 based on monitoring hematological parameter platelet count via lab test

    Time frame: 26 weeks

  15. Evaluate descriptively the safety and tolerability of OctaAlpha1 based on monitoring hepatic parameter alanine aminotransferase

    Evaluate descriptively the safety and tolerability of OctaAlpha1 based on monitoring hepatic parameter alanine aminotransferase via lab test

    Time frame: 26 weeks

  16. Evaluate descriptively the safety and tolerability of OctaAlpha1 based on monitoring hepatic parameter aspartate aminotransferase

    Evaluate descriptively the safety and tolerability of OctaAlpha1 based on monitoring hepatic parameter aspartate aminotransferase via lab test

    Time frame: 26 weeks

  17. Evaluate descriptively the safety and tolerability of OctaAlpha1 based on monitoring renal parameter creatinine

    Evaluate descriptively the safety and tolerability of OctaAlpha1 based on monitoring renal parameter creatinine via lab test

    Time frame: 26 weeks

  18. Evaluate descriptively the safety and tolerability of OctaAlpha1 based on monitoring renal parameter Blood Urea Nitrogen (BUN)

    Evaluate descriptively the safety and tolerability of OctaAlpha1 based on monitoring renal parameter Blood Urea Nitrogen (BUN) via lab test

    Time frame: 26 weeks

  19. Evaluate descriptively the safety and tolerability of OctaAlpha1 based on viral safety (HAV, HBV, HCV, HIV-1/2, HN, and parvovirus B19)

    Evaluate descriptively the safety and tolerability of OctaAlpha1 based on viral safety (HAV, HBV, HCV, HIV-1/2, HN, and parvovirus B19)

    Time frame: 26 weeks

  20. Trough Levels of A1PI

    Investigate descriptively the trough levels of A1PI and anti-NE capacity of OctaAlpha1 compared to Glassia®

    Time frame: 26 weeks

  21. Pharmacodynamics of OctaAlpha1 measuring Pulmonary function tests

    Investigate the pharmacodynamics of OctaAlpha1 measuring Pulmonary function tests (done according to the American Thoracic Society/European Respiratory Society Taskforce Standardisation of Lung Function Testing guideline)

    Time frame: 26 weeks

  22. Investigate the pharmacodynamics of OctaAlpha1 measuring Induced sputum test measuring the amount of functional and total A1PI in the airway lining fluid of the lung.

    Investigate the pharmacodynamics of OctaAlpha1 measuring Induced sputum test measuring the amount of functional and total A1PI in the airway lining fluid of the lung.

    Time frame: 26 weeks

  23. Investigate the pharmacodynamics of OctaAlpha1 measuring Induced sputum test measuring the amount of functional and total LTB4 in the airway lining fluid of the lung.

    Investigate the pharmacodynamics of OctaAlpha1 measuring Induced sputum test measuring the amount of functional and total LTB4 in the airway lining fluid of the lung.

    Time frame: 26 weeks

  24. Investigate the pharmacodynamics of OctaAlpha1 measuring antibodies to A1PI using normal ranges of the central laboratory

    Investigate the pharmacodynamics of OctaAlpha1 measuring antibodies to A1PI using normal ranges of the central laboratory

    Time frame: 26 weeks

  25. Determine PK parameters of the A1PI serum concentration versus time curve following a single dose of OctaAlpha1

    Determine PK parameters of the A1PI serum concentration versus time curve following a single dose of OctaAlpha1

    Time frame: 26 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jul 2018; primary completion for Dec 2019, 17 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2017
First posted
Dec 28, 2017
StartEst.
Jul 2018
Primary completionEst.
Dec 2019
CompletionEst.
Dec 2019
Last update
Apr 10, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 10, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03385395
Lead sponsor
Octapharma
Responsible party
Sponsor
First posted
Dec 28, 2017
Start date
Jul 2018 (estimated)
Primary completion
Dec 2019 (estimated)
Completion
Dec 2019 (estimated)
Last update
Apr 10, 2018

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion